You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMoexipril
Accession NumberDB00691  (APRD01120)
TypeSmall Molecule
GroupsApproved
DescriptionMoexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.
Structure
Thumb
Synonyms
Moexipril
Moexiprilum
Uniretic
Univasc
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
UnivascTablet, film coated7.5 mg/1OralUCB, Inc.1995-07-15Not applicableUs
UnivascTablet, film coated15 mg/1OralUCB, Inc.1995-07-152016-02-25Us
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Moexipril HydrochlorideTablet, film coated7.5 mg/1OralAvera Mc Kennan Hospital2015-08-10Not applicableUs
Moexipril HydrochlorideTablet15 mg/1OralPhysicians Total Care, Inc.2004-04-27Not applicableUs
Moexipril HydrochlorideTablet, film coated7.5 mg/1OralCarilion Materials Management2003-05-08Not applicableUs
Moexipril HydrochlorideTablet, film coated7.5 mg/1OralTeva Pharmaceuticals USA Inc2003-05-08Not applicableUs
Moexipril HydrochlorideTablet7.5 mg/1OralPhysicians Total Care, Inc.2008-08-14Not applicableUs
Moexipril HydrochlorideTablet, film coated15 mg/1OralGlenmark Pharmaceuticals Inc., Usa2010-12-31Not applicableUs
Moexipril HydrochlorideTablet, film coated15 mg/1OralTeva Pharmaceuticals USA Inc2003-05-08Not applicableUs
Moexipril HydrochlorideTablet7.5 mg/1OralApotex Corp.2008-06-09Not applicableUs
Moexipril HydrochlorideTablet, film coated7.5 mg/1OralGlenmark Pharmaceuticals Inc., Usa2010-12-31Not applicableUs
Moexipril HydrochlorideTablet15 mg/1OralApotex Corp.2008-06-09Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Moexipril Hydrochloride and HydrochlorothiazideHeritage Pharmaceuticals Inc.
Salts
Name/CASStructureProperties
Moexipril Hydrochloride
82586-52-5
Thumb
  • InChI Key: JXRAXHBVZQZSIC-JKVLGAQCSA-N
  • Monoisotopic Mass: 534.213279191
  • Average Mass: 535.029
DBSALT000504
Categories
UNIIWT87C52TJZ
CAS number103775-10-6
WeightAverage: 498.5681
Monoisotopic: 498.236601452
Chemical FormulaC27H34N2O7
InChI KeyUWWDHYUMIORJTA-HSQYWUDLSA-N
InChI
InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1
IUPAC Name
(3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[[email protected]]1C(O)=O
Pharmacology
IndicationFor the treatment of hypertension.
Structured Indications
PharmacodynamicsMoexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.
Mechanism of actionMoexipril is a prodrug for moexiprilat, which inhibits ACE in humans and animals. The mechanism through which moexiprilat lowers blood pressure is believed to be primarily inhibition of ACE activity. ACE is a peptidyl dipeptidase that catalyzes the conversion of the inactive decapeptide angiotensin I to the vasoconstrictor substance angiotensin II. Angiotensin II is a potent peripheral vasoconstrictor that also stimulates aldosterone secretion by the adrenal cortex and provides negative feedback on renin secretion. ACE is identical to kininase II, an enzyme that degrades bradykinin, an endothelium-dependent vasodilator. Moexiprilat is about 1000 times as potent as moexipril in inhibiting ACE and kininase II. Inhibition of ACE results in decreased angiotensin II formation, leading to decreased vasoconstriction, increased plasma renin activity, and decreased aldosterone secretion. The latter results in diuresis and natriuresis and a small increase in serum potassium concentration (mean increases of about 0.25 mEq/L were seen when moexipril was used alone). Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of moexipril remains to be elucidated. Although the principal mechanism of moexipril in blood pressure reduction is believed to be through the renin-angiotensin-aldosterone system, ACE inhibitors have some effect on blood pressure even in apparent low-renin hypertension.
TargetKindPharmacological actionActionsOrganismUniProt ID
Angiotensin-converting enzymeProteinyes
inhibitor
HumanP12821 details
Angiotensin-converting enzyme 2Proteinyes
inhibitor
HumanQ9BYF1 details
Related Articles
AbsorptionMoexipril is incompletely absorbed, with bioavailability as moexiprilat of about 13% compared to intravenous (I.V.) moexipril (both measuring the metabolite moexiprilat), and is markedly affected by food, which reduces Cmax and AUC by about 70% and 40%, respectively, after the ingestion of a low-fat breakfast or by 80% and 50%, respectively, after the ingestion of a high-fat breakfast.
Volume of distribution
  • 183 L
Protein bindingMoexiprilat is approxomately 50% protein bound.
Metabolism

Rapidly converted to moexiprilat, the active metabolite. Conversion to the active metabolite is thought to require carboxyesterases and is likely to occur in organs or tissues, other than the gastrointestinal tract, in which carboxyesterases occur. The liver is thought to be one site of conversion, but not the primary site.

SubstrateEnzymesProduct
Moexipril
Not Available
MoexiprilatDetails
Route of eliminationMoexiprilat undergoes renal elimination.
Half lifeMoexipril elimination half-life is approximately 1 hour. Moexiprilat elimination half-life is 2 to 9 hours.
Clearance
  • 441 mL/min
ToxicityHuman overdoses of moexipril have not been reported. In case reports of overdoses with other ACE inhibitors, hypotension has been the principal adverse effect noted. Single oral doses of 2 g/kg moexipril were associated with significant lethality in mice. Rats, however, tolerated single oral doses of up to 3 g/kg. Common adverse effects include cough, dizziness, diarrhea, flu syndrome, fatigue, pharyngitis, flushing, rash, and myalgia
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Moexipril Metabolism PathwayDrug metabolismSMP00595
Moexipril Action PathwayDrug actionSMP00151
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Moexipril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Moexipril.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Moexipril is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Moexipril is combined with Aceclofenac.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Moexipril is combined with Acetovanillone.Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Moexipril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Moexipril is combined with Adapalene.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Moexipril.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Moexipril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Moexipril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Moexipril.Approved
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Moexipril.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Moexipril.Approved, Illicit, Investigational
AlprenololMoexipril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanMoexipril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Moexipril.Experimental
AmifostineMoexipril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Moexipril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Moexipril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Moexipril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Moexipril.Approved
AmiodaroneMoexipril may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Moexipril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Moexipril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Moexipril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Moexipril is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Moexipril is combined with Amyl Nitrite.Approved
AnagrelideMoexipril may increase the QTc-prolonging activities of Anagrelide.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Moexipril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Moexipril is combined with Antipyrine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Moexipril is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Moexipril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Moexipril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Moexipril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Moexipril.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Moexipril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Moexipril is combined with Arotinolol.Approved
Arsenic trioxideMoexipril may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherMoexipril may increase the QTc-prolonging activities of Artemether.Approved
AsenapineMoexipril may increase the QTc-prolonging activities of Asenapine.Approved
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Moexipril.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Moexipril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Azapropazone.Withdrawn
AzathioprineMoexipril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Moexipril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Moexipril.Approved
AzithromycinMoexipril may increase the QTc-prolonging activities of Azithromycin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Moexipril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Moexipril.Experimental
BarbitalBarbital may increase the hypotensive activities of Moexipril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Moexipril is combined with Barnidipine.Approved
BedaquilineMoexipril may increase the QTc-prolonging activities of Bedaquiline.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Moexipril.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Moexipril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Moexipril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Moexipril.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Benoxaprofen.Withdrawn
BepridilMoexipril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Moexipril.Approved
BethanidineBethanidine may increase the hypotensive activities of Moexipril.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Moexipril is combined with Betulinic Acid.Investigational
BimatoprostMoexipril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Moexipril.Approved
BoceprevirThe serum concentration of Moexipril can be decreased when it is combined with Boceprevir.Approved
BortezomibThe risk or severity of adverse effects can be increased when Moexipril is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Moexipril.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Moexipril is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Moexipril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Moexipril.Approved
BromfenacThe risk or severity of adverse effects can be increased when Moexipril is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Moexipril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Moexipril is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Moexipril is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Moexipril is combined with Bupivacaine.Approved, Investigational
BupranololMoexipril may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Moexipril.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Moexipril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Moexipril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Moexipril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Captopril.Approved
CarbamazepineThe metabolism of Moexipril can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Moexipril is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Moexipril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Moexipril.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Moexipril is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Moexipril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Celecoxib.Approved, Investigational
CeliprololMoexipril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibMoexipril may increase the QTc-prolonging activities of Ceritinib.Approved
CertoparinCertoparin may increase the hyperkalemic activities of Moexipril.Approved
ChloroquineMoexipril may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Moexipril is combined with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Moexipril.Withdrawn
ChlorpromazineMoexipril may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Moexipril.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Moexipril is combined with Cilnidipine.Approved
CiprofloxacinMoexipril may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CiprofloxacinMoexipril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Moexipril.Approved, Investigational, Withdrawn
CitalopramMoexipril may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Moexipril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Moexipril is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Moexipril is combined with Clofarabine.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Moexipril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Moexipril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Moexipril is combined with Clonixin.Approved
ClozapineMoexipril may increase the QTc-prolonging activities of Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Moexipril is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Moexipril.Approved
CrizotinibMoexipril may increase the QTc-prolonging activities of Crizotinib.Approved
CryptenamineMoexipril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Moexipril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Moexipril.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Moexipril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Moexipril.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Moexipril is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Moexipril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Moexipril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Moexipril.Investigational
DebrisoquinMoexipril may increase the hypotensive activities of Debrisoquin.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Moexipril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Moexipril.Investigational
DeserpidineMoexipril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Moexipril is combined with Desflurane.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Moexipril.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Moexipril.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Moexipril.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Moexipril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Diclofenamide.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Moexipril.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Moexipril.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Moexipril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Moexipril.Approved
DihydralazineMoexipril may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Moexipril.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Moexipril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Moexipril is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Moexipril is combined with Dipyridamole.Approved
DisopyramideMoexipril may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideMoexipril may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronMoexipril may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneMoexipril may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DorzolamideMoexipril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Moexipril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Moexipril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Moexipril.Approved
DronedaroneMoexipril may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolMoexipril may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DrospirenoneMoexipril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Droxicam.Approved
DuloxetineMoexipril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Moexipril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Moexipril.Approved
E6201The risk or severity of adverse effects can be increased when Moexipril is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Moexipril is combined with Ebselen.Investigational
EfonidipineMoexipril may increase the hypotensive activities of Efonidipine.Approved
EliglustatMoexipril may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Moexipril is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Moexipril.Approved, Vet Approved
EnalaprilatMoexipril may increase the hypotensive activities of Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Moexipril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Moexipril.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Moexipril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Moexipril.Approved
EpoprostenolMoexipril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Moexipril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Moexipril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Moexipril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Moexipril.Approved
ErythromycinMoexipril may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramMoexipril may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Moexipril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Moexipril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Moexipril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Moexipril.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Moexipril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Moexipril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Moexipril is combined with Etanercept.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Moexipril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Moexipril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Moexipril is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Moexipril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Moexipril is combined with Evening primrose oil.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Moexipril.Approved
exisulindThe risk or severity of adverse effects can be increased when Moexipril is combined with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Moexipril is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Moexipril is combined with Fenbufen.Approved
FenoldopamMoexipril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Fenoprofen.Approved
FimasartanThe risk or severity of adverse effects can be increased when Moexipril is combined with Fimasartan.Approved
FlecainideMoexipril may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloctafenineThe risk or severity of adverse effects can be increased when Moexipril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Moexipril is combined with Flunixin.Vet Approved
FluoxetineMoexipril may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolMoexipril may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FlurbiprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Moexipril.Experimental
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Moexipril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Moexipril.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Moexipril is combined with Furosemide.Approved, Vet Approved
Gadobenic acidMoexipril may increase the QTc-prolonging activities of Gadobenic acid.Approved
GarlicThe serum concentration of Moexipril can be decreased when it is combined with Garlic.Approved
GemifloxacinMoexipril may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GoserelinMoexipril may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronMoexipril may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanabenzGuanabenz may increase the hypotensive activities of Moexipril.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Moexipril.Approved
GuanethidineMoexipril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Moexipril is combined with Guanfacine.Approved, Investigational
HaloperidolMoexipril may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Moexipril is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Moexipril.Approved, Investigational
HexamethoniumMoexipril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Moexipril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Moexipril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Moexipril is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Moexipril is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Moexipril.Approved
HydralazineThe risk or severity of adverse effects can be increased when Moexipril is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Moexipril is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideMoexipril may increase the hypotensive activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Moexipril is combined with Ibuproxam.Withdrawn
IbutilideMoexipril may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantIcatibant may decrease the antihypertensive activities of Moexipril.Approved
IloperidoneMoexipril may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Moexipril.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Moexipril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Indapamide.Approved
IndenololMoexipril may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Moexipril is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Indoprofen.Withdrawn
IndoraminMoexipril may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Moexipril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Moexipril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Moexipril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Moexipril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Moexipril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Moexipril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Moexipril is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Moexipril is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Moexipril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Moexipril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Moexipril.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Kebuzone.Experimental
KetanserinMoexipril may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Moexipril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Moexipril.Approved
LacidipineMoexipril may increase the hypotensive activities of Lacidipine.Approved
Lanthanum carbonateThe serum concentration of Moexipril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Moexipril.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Moexipril is combined with Leflunomide.Approved, Investigational
LenvatinibMoexipril may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Moexipril.Approved, Investigational
LeuprolideMoexipril may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Moexipril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Moexipril is combined with Levobupivacaine.Approved
LevodopaMoexipril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinMoexipril may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Moexipril is combined with Levosimendan.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Moexipril.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Moexipril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Moexipril.Approved
LofexidineMoexipril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirMoexipril may increase the QTc-prolonging activities of Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Moexipril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Moexipril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Loxoprofen.Approved
LumefantrineMoexipril may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Lumiracoxib.Approved, Investigational
MacitentanMoexipril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Moexipril is combined with Magnesium salicylate.Approved
ManidipineMoexipril may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Moexipril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Moexipril is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Moexipril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Moexipril.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Moexipril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Moexipril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Moexipril is combined with Metamizole.Withdrawn
MethadoneMoexipril may increase the QTc-prolonging activities of Methadone.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Moexipril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Moexipril.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Moexipril.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Moexipril is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Moexipril.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Moexipril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Moexipril.Approved
MetipranololThe risk or severity of adverse effects can be increased when Moexipril is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Moexipril.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Moexipril.Approved, Investigational
MetyrosineMoexipril may increase the hypotensive activities of Metyrosine.Approved
MibefradilMoexipril may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Moexipril.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Moexipril.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Moexipril.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Moexipril.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Moexipril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Moexipril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Moexipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Moexipril is combined with Morphine.Approved, Investigational
MoxifloxacinMoexipril may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineMoexipril may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Moexipril is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Moexipril is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Moexipril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Moexipril is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Moexipril is combined with Naftifine.Approved
NaftopidilMoexipril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Moexipril is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Moexipril is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Moexipril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Moexipril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Moexipril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Moexipril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Moexipril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Moexipril.Approved
NicorandilNicorandil may increase the hypotensive activities of Moexipril.Approved
NifedipineThe risk or severity of adverse effects can be increased when Moexipril is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Moexipril is combined with Niflumic Acid.Approved
NiguldipineMoexipril may increase the hypotensive activities of Niguldipine.Experimental
NilotinibMoexipril may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineMoexipril may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Moexipril is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Moexipril.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Moexipril.Approved
NitrendipineMoexipril may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Moexipril is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Moexipril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Moexipril is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Moexipril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Moexipril.Approved
ObinutuzumabMoexipril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Moexipril.Withdrawn
OfloxacinMoexipril may increase the QTc-prolonging activities of Ofloxacin.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Moexipril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Moexipril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Moexipril is combined with Olsalazine.Approved
OmapatrilatMoexipril may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronMoexipril may increase the QTc-prolonging activities of Ondansetron.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Moexipril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Moexipril is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Moexipril is combined with Oxaprozin.Approved
OxprenololMoexipril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Moexipril is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneMoexipril may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatMoexipril may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Moexipril is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Moexipril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Moexipril.Approved
PazopanibMoexipril may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololThe risk or severity of adverse effects can be increased when Moexipril is combined with Penbutolol.Approved, Investigational
PentamidineMoexipril may increase the QTc-prolonging activities of Pentamidine.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Moexipril.Approved, Vet Approved
PentoliniumMoexipril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Moexipril.Approved, Investigational
PerflutrenMoexipril may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Moexipril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Moexipril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Moexipril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Moexipril.Approved
PhenoxybenzamineMoexipril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Moexipril.Withdrawn
PhentolamineMoexipril may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Moexipril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Moexipril.Approved
PinacidilMoexipril may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Moexipril is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Pipamperone.Approved
PiretanidePiretanide may increase the hypotensive activities of Moexipril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Moexipril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Moexipril.Withdrawn
PolythiazideMoexipril may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Moexipril is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Moexipril.Approved
PregabalinThe risk or severity of adverse effects can be increased when Moexipril is combined with Pregabalin.Approved, Illicit, Investigational
PrimaquineMoexipril may increase the QTc-prolonging activities of Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Moexipril.Approved, Vet Approved
ProcainamideMoexipril may increase the QTc-prolonging activities of Procainamide.Approved
PromazineMoexipril may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Moexipril is combined with Propacetamol.Approved
PropafenoneMoexipril may increase the QTc-prolonging activities of Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Moexipril is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Moexipril.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Moexipril.Approved
PTC299The risk or severity of adverse effects can be increased when Moexipril is combined with PTC299.Investigational
QuetiapineMoexipril may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Quinapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Moexipril.Approved
QuinidineMoexipril may increase the QTc-prolonging activities of Quinidine.Approved
QuinineMoexipril may increase the QTc-prolonging activities of Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Moexipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Moexipril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Moexipril is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Moexipril.Approved
RescinnamineMoexipril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Moexipril.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Moexipril is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Moexipril.Approved
RilmenidineMoexipril may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Moexipril.Approved
RisperidoneMoexipril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabMoexipril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Moexipril is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Moexipril is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Moexipril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Moexipril is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Moexipril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Moexipril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Moexipril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Moexipril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Moexipril.Experimental
SaquinavirMoexipril may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Moexipril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Moexipril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Moexipril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Moexipril.Approved, Investigational, Vet Approved
SelexipagMoexipril may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Moexipril is combined with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Moexipril is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Moexipril.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Moexipril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Moexipril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Moexipril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Moexipril.Approved, Investigational
SitaxentanMoexipril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Moexipril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Moexipril is combined with Sodium Nitrite.Approved
SotalolMoexipril may increase the QTc-prolonging activities of Sotalol.Approved
SpiraprilMoexipril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Moexipril.Approved
SRT501The risk or severity of adverse effects can be increased when Moexipril is combined with SRT501.Investigational
St. John's WortThe metabolism of Moexipril can be increased when combined with St. John's Wort.Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Moexipril is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Moexipril is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Moexipril is combined with Sulfasalazine.Approved
SulfisoxazoleMoexipril may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Moexipril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Suprofen.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Moexipril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Moexipril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Moexipril.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Moexipril is combined with Tamsulosin.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Moexipril.Approved
TelavancinMoexipril may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinMoexipril may increase the QTc-prolonging activities of Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Moexipril.Approved, Investigational
TemocaprilMoexipril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Moexipril is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Moexipril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Moexipril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Moexipril is combined with Teriflunomide.Approved
TerlipressinMoexipril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineMoexipril may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Moexipril is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Moexipril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Moexipril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Moexipril.Approved, Vet Approved
ThioridazineMoexipril may increase the QTc-prolonging activities of Thioridazine.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Moexipril.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Tiaprofenic acid.Approved
TiboloneMoexipril may increase the hypotensive activities of Tibolone.Approved
TicrynafenMoexipril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Moexipril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Moexipril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Moexipril.Approved
TipranavirThe serum concentration of Moexipril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Moexipril.Approved
TolazolineMoexipril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Moexipril is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Moexipril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Moexipril is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Moexipril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Moexipril.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Moexipril.Approved
ToremifeneMoexipril may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Moexipril.Approved
TranilastThe risk or severity of adverse effects can be increased when Moexipril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Moexipril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Moexipril.Approved
TravoprostTravoprost may increase the hypotensive activities of Moexipril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Moexipril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Moexipril is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Moexipril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Moexipril.Approved
TrichlormethiazideMoexipril may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinMoexipril may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanMoexipril may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Moexipril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Moexipril.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Moexipril is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Moexipril.Approved, Investigational
UnoprostoneMoexipril may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Moexipril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Moexipril.Approved, Investigational
VandetanibMoexipril may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the antihypertensive activities of Moexipril.Approved
VemurafenibMoexipril may increase the QTc-prolonging activities of Vemurafenib.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Moexipril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Moexipril.Approved, Investigational
VinpocetineMoexipril may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineMoexipril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Moexipril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Moexipril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Moexipril is combined with Zileuton.Approved, Investigational, Withdrawn
ZiprasidoneMoexipril may increase the QTc-prolonging activities of Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Moexipril is combined with Zomepirac.Withdrawn
ZuclopenthixolMoexipril may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Herbs that may attenuate the antihypertensive effect of moexipril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of moexipril.
  • Moexipril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
  • Take moexipril one hour before or two hours after meals.
References
Synthesis ReferenceNot Available
General References
  1. Asmar R, Sayegh F, Tracz W, Hlawaty M, Olszowska M, Jourde M, Vincent M, Goujoun B, Maldonado J: Reversal of left ventricular hypertrophy with the ACE inhibitor moexipril in patients with essential hypertension. Acta Cardiol. 2002 Feb;57(1):31-2. [PubMed:11918132 ]
  2. Blacher J, Raison J, Amah G, Schiemann AL, Stimpel M, Safar ME: Increased arterial distensibility in postmenopausal hypertensive women with and without hormone replacement therapy after acute administration of the ACE inhibitor moexipril. Cardiovasc Drugs Ther. 1998 Sep;12(4):409-14. [PubMed:9825188 ]
  3. Brogden RN, Wiseman LR: Moexipril. A review of its use in the management of essential hypertension. Drugs. 1998 Jun;55(6):845-60. [PubMed:9617599 ]
  4. Cawello W, Boekens H, Waitzinger J, Miller U: Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition. Int J Clin Pharmacol Ther. 2002 Jan;40(1):9-17. [PubMed:11837383 ]
  5. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. [PubMed:15286086 ]
  6. Chrysant SG, Chrysant GS: Pharmacological profile and clinical use of moexipril. Expert Rev Cardiovasc Ther. 2003 Sep;1(3):345-52. [PubMed:15030263 ]
  7. Chrysant GS, Nguyen PK: Moexipril and left ventricular hypertrophy. Vasc Health Risk Manag. 2007;3(1):23-30. [PubMed:17583172 ]
  8. Grass GM, Morehead WT: Evidence for site-specific absorption of a novel ACE inhibitor. Pharm Res. 1989 Sep;6(9):759-65. [PubMed:2554270 ]
  9. Kalasz H, Petroianu G, Tekes K, Klebovich I, Ludanyi K, Gulyas Z: Metabolism of moexipril to moexiprilat: determination of in vitro metabolism using HPLC-ES-MS. Med Chem. 2007 Jan;3(1):101-6. [PubMed:17266629 ]
  10. Persson B, Stimpel M: Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. Eur J Clin Pharmacol. 1996;50(4):259-64. [PubMed:8803515 ]
  11. Spinar J, Vitovec J: MORE--MOexipril and REgression of left ventricle hypertrophy in combination therapy A multicentric open label clinical trial. Int J Cardiol. 2005 Apr 20;100(2):199-206. [PubMed:15823625 ]
  12. Stimpel M, Koch B, Oparil S: Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). Cardiology. 1998 May;89(4):271-6. [PubMed:9643274 ]
  13. White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy. 1998 May-Jun;18(3):588-99. [PubMed:9620109 ]
  14. White WB, Whelton A, Fox AA, Stimpel M, Kaihlanen PM: Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring. J Clin Pharmacol. 1995 Mar;35(3):233-8. [PubMed:7608310 ]
External Links
ATC CodesC09AA13C09BA13
AHFS Codes
  • 24:32.04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5775
Blood Brain Barrier-0.9022
Caco-2 permeable-0.7313
P-glycoprotein substrateSubstrate0.9085
P-glycoprotein inhibitor IInhibitor0.5919
P-glycoprotein inhibitor IIInhibitor0.8157
Renal organic cation transporterNon-inhibitor0.8146
CYP450 2C9 substrateNon-substrate0.8588
CYP450 2D6 substrateNon-substrate0.8369
CYP450 3A4 substrateSubstrate0.7014
CYP450 1A2 substrateNon-inhibitor0.8205
CYP450 2C9 inhibitorNon-inhibitor0.5961
CYP450 2D6 inhibitorNon-inhibitor0.8261
CYP450 2C19 inhibitorNon-inhibitor0.6592
CYP450 3A4 inhibitorNon-inhibitor0.5935
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6861
Ames testNon AMES toxic0.8358
CarcinogenicityNon-carcinogens0.9378
BiodegradationNot ready biodegradable0.9762
Rat acute toxicity2.5131 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9715
hERG inhibition (predictor II)Inhibitor0.8751
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc
  • Glenmark generics ltd
  • Paddock laboratories inc
  • Teva pharmaceuticals usa inc
  • Schwarz pharma inc
Packagers
Dosage forms
FormRouteStrength
TabletOral15 mg/1
TabletOral7.5 mg/1
Tablet, film coatedOral
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral7.5 mg/1
Prices
Unit descriptionCostUnit
Univasc 15 mg tablet2.44USD tablet
Univasc 7.5 mg tablet2.13USD tablet
Moexipril hcl 15 mg tablet1.48USD tablet
Moexipril hcl 7.5 mg tablet1.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySoluble (about 10% weight-to-volume) in distilled water at room temperature as HCl salt.Not Available
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00585 mg/mLALOGPS
logP1.52ALOGPS
logP1.5ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)3.46ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area114.4 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity132.88 m3·mol-1ChemAxon
Polarizability53.55 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • Alpha-amino acid ester
  • Alpha-amino acid amide
  • Tetrahydroisoquinoline
  • Phenylpropylamine
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Anisole
  • Aralkylamine
  • Fatty acid ester
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. [PubMed:15286086 ]
  3. Edling O, Bao G, Feelisch M, Unger T, Gohlke P: Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63. [PubMed:7473177 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Carboxypeptidase which converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin-13 and dynorphin-13 with high efficiency. May be an important regulator of heart function.(Microbial infection) Acts as a receptor for SARS coronavirus/SARS-CoV and human coronavirus NL63/HCoV-NL63.
Gene Name:
ACE2
Uniprot ID:
Q9BYF1
Molecular Weight:
92462.4 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. [PubMed:15286086 ]
  3. Edling O, Bao G, Feelisch M, Unger T, Gohlke P: Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63. [PubMed:7473177 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11